DivInc has announced a new program that will support BIPOC and women founders of social enterprise startups working on Web3 technology. Photo via divinc.org

A Texas accelerator that's focused on supporting traditionally marginalized entrepreneurs has announced its newest program.

DivInc has introduced DWeb for Social Impact Accelerator, a new program set to support BIPOC and women founders of social enterprise startups developing global solutions with DWeb and Web3 technologies — such as blockchain, crypto-asset, artificial intelligence, machine learning, augmented reality, and more.

The first cohort of the program, which is supported by the Filecoin Foundation for the Decentralized Web, or FFDW, will run from September through November at the Ion. Applications are open now.

"Through the DWeb for Social Impact Accelerator we are marrying activism with the decentralized web in a way that builds these startups and puts them at the forefront of solving society's toughest challenges," says Preston James, CEO at DivInc, in a news release. "We want to see our creative tech economy founders playing a major role in building and benefiting from DWeb and Web3 for the greater good. This partnership with FFDW is a huge leap forward in that pursuit."

The 12-week accelerator will support up to 10 companies, and, at the end of the program, each selected company will receive $10,000 in non-dilutive seed funding. In addition to FFDW, the program is supported by Houston Premier Partners, J.P. Morgan Chase & Co., Verizon, The Ion, and Mercury.

"A core part of FFDW's mission is education about the decentralized web," says Marta Belcher, president and chair of Filecoin Foundation for the Decentralized Web, in the release. "FFDW is absolutely thrilled to bring more diverse voices into the Web3 ecosystem."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.